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Aims__ Dysregulation of autonomic nervous system activity can trigger ventricular 
arrhythmias and sudden death in patients with heart failure.  N-type Ca2+ channels (NCCs) 
play an important role in sympathetic nervous system activation by regulating the calcium 
entry that triggers release of neurotransmitters from peripheral sympathetic nerve terminals.  
We have investigated the ability of NCC blockade to prevent lethal arrhythmias associated 
with heart failure. 
Methods and Results__ We compared the effects of cilnidipine, a dual N- and L-type Ca2+ 
channel blocker, with those of nitrendipine, a selective L-type Ca2+ channel blocker, in 
transgenic mice expressing a cardiac-specific, dominant-negative form of neuron-restrictive 
silencer factor (dnNRSF-Tg).  In this mouse model of dilated cardiomyopathy leading to 
sudden arrhythmic death, cardiac structure and function did not significantly differ among the 
control, cilnidipine and nitrendipine groups.  However, cilnidipine dramatically reduced 
arrhythmias in dnNRSF-Tg mice, significantly improving their survival rate and correcting 
the imbalance between cardiac sympathetic and parasympathetic nervous system activity.  A 
β-blocker, bisoprolol, showed similar effects in these mice.  Genetic titration of NCCs, 
achieved by crossing dnNRSF-Tg mice with mice lacking CACNA1B, which encodes the α1 
subunit of NCCs, improved survival rate.  With restoration of cardiac autonomic balance, 
dnNRSF-Tg;CACNA1B+/- mice showed fewer malignant arrhythmias than 
dnNRSF-Tg;CACNA1B+/+ mice. 
Conclusions__ Both pharmacological blockade of NCCs and their genetic titration improved 
cardiac autonomic balance and prevented lethal arrhythmias in a mouse model of dilated 
cardiomyopathy and sudden arrhythmic death.  Our findings suggest NCC blockade is a 
potentially useful approach to preventing sudden death in patients with heart failure. 
  









Approximately 50% of deaths among patients with heart failure are classified as sudden death, 
mainly caused by lethal arrhythmias1.  Despite recent progress, pharmacological 
interventions for the treatment and prevention of lethal arrhythmias associated with chronic 
heart failure remain unsatisfactory.  Nonetheless, it is anticipated that a better understanding 
of the molecular basis of arrhythmicity in failing hearts will enable identification of 
therapeutic targets that can serve as the basis for the development of new pharmacological 
treatments.  
Autonomic dysregulation leading to increased sympathetic nerve activity and 
decreased parasympathetic nerve activity contributes to the increased arrhythmicity seen in 
patients with chronic heart failure2, 3.  N-type voltage-dependent Ca2+ channels (NCCs), 
encoded by the CACNA1B (α1B subunit) gene, are predominantly localized in the nervous 
system, where they play a pivotal role in modulating a variety of neuronal functions, 
including neurotransmitter release at sympathetic nerve terminals4-6.  Mice lacking 
CACNA1B show functional deterioration of their sympathetic nervous system7, and the ability 
of NCC blockade to prevent malignant arrhythmias and sudden death associated with heart 
failure remains unevaluated.  
We previously reported that transgenic mice cardiac-selectively expressing a 
dominant-negative form of neuron-restrictive silencer factor (NRSF, also called REST) 
(dnNRSF-Tg), a transcriptional repressor important for regulation of the fetal cardiac gene 
program, showed progressive cardiomyopathy and sudden arrhythmic death beginning at 
about 8 weeks of age8. We have also reported several abnormalities in cardiac 
electrophysiological properties and ion channel expression in these dnNRSF-Tg mice9, 10. The 
dnNRSF-Tg hearts showed increased expression of fetal type ion channel genes, including 
CACNA1H, which encodes the T-type Ca2+ channel (TCC) α1 subunit, and a corresponding 
increase in Ica,T amplitude8.  In that earlier study, we demonstrated that TCC blockade could 
prevent sudden death in dnNRSF-Tg mice by both restoring the normal electrophysiology of 
ventricular myocytes and correcting the cardiac autonomic dysfunction observed in 
dnNRSF-Tg mice11.  Because TCC expression, and thus functional TCC currents, is 
increased in the myocardium of dnNRSF-Tg mice, TCC blockade directly affects the 
electrophysiological properties of ventricular myocytes in dnNRSF-Tg mice.  On the other 
hand, the impact of modulating autonomic nervous system balance on the incidence of lethal 
arrhythmias in dnNRSF-Tg mice remains unclear.   
Pharmacological blockade or genetic deletion of NCCs reportedly alters autonomic 
activity in both human patients and animal models7, 12, 13.  On the other hand, little or no 
NCC expression has been detected in the ventricular myocardium.  Therefore, to evaluate 





associated with heart failure, we assessed the effects of pharmacological blockade of NCCs 
and their genetic titration on arrhythmicity and sudden death in dnNRSF-Tg mice.  Our 
findings demonstrate the importance of an imbalance between sympathetic and 
parasympathetic nerve activities in the generation of lethal arrhythmias in failing hearts, and 
suggest restoring autonomic nervous system balance through NCC inhibition can be an 






An expanded Methods section is available in Supplemental Material online.  
 
2.1 Animal experiments  
The animal care and all experimental protocols were reviewed and approved by the 
Animal Research Committee at Kyoto University Graduate School of Medicine, and 
conformed to the US National Institute of Health Guide for the Care and Use of Laboratory 
Animals.  Beginning at 8 weeks of age, dnNRSF-Tg mice were left untreated (control) or 
were treated for 24 weeks with cilnidipine (10 mg/kg/day P.O.) or nitrendipine (10 mg/kg/day 
P.O.). The drug dosages were chosen based on earlier reports and our preliminary studies14, 15. 
Cilnidipine was supplied by Mochida Pharmaceutical Co, Ltd. (Tokyo, Japan).  Nitrendipine 
was purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan).  Bisoprolol was 
supplied by Mitsubishi Tanabe Pharma Corporation (Osaka, Japan).  Cilnidipine exerts a 
much more potent inhibitory effect on N-type Ca2+ currents than does nitrendipine, which has 
little effect on N-type Ca2+ currents, particularly under conditions in which L-type Ca2+ 
current inhibition is comparable between the two drugs16, 17. We then selected the doses of 
both drugs that similarly and minimally affected blood pressure. In another experiment, 
dnNRSF-Tg mice were bred with CACNA1B heterozygous knockout mice to obtain 
dnNRSF-Tg;CACNA1B+/- mice and control dnNRSF-Tg;CACNA1B+/+ littermates. 
CACNA1B+/- mice were described in an earlier report7. For the isolation and analysis of 
hearts, mice were anesthetized with 3.0 % of isoflurane and sacrificed by cervical dislocation. 
    
2.2 Statistical Analysis 
Data are presented as means ± standard errors of the mean (SEM) unless indicated otherwise.   
Survival was analyzed using the Kaplan-Meier method with the log-rank test. Comparisons 
among multiple groups were made using ANOVA with post hoc Fisher’s tests, except for 
numbers of arrhythmias. Values of p<0.05 were considered significant. Numbers of 
arrhythmias between two groups were analyzed using the Mann-Whitney test.  Values of 
p<0.05 were considered significant. Numbers of arrhythmias among four groups were 
analyzed using Kruskal-Wallis nonparametric ANOVA followed by the Bonferroni correction. 








3.1 The dual N- and L-type Ca2+ channel blocker cilnidipine improves survival among 
dnNRSF-Tg mice without affecting cardiac structure or function  
  We initially confirmed that there is little expression of CACNA1B, encoding the α1 subunit 
of NCCs, in either wild-type or dnNRSF-Tg hearts, which is in contrast to its obvious 
expression in brain (Figure 1A).  On the other hand, we detected substantially greater 
ventricular expression of CACNA1H, encoding the α1 subunit of TCCs, and CACNA1C, 
encoding the α1 subunit of L-type Ca2+ channels (Figure 1B).  Although ventricular 
expression of CACNA1B is increased in dnNRSF-Tg hearts, probably due to the presence of 
NRSF-binding element in the gene, the levels are still lower than those of CACNA1H in 
wild-type hearts, where no functional T-type Ca2+currents are detected11, 18.  To evaluate the 
potential therapeutic effect of modulating autonomic nervous system activity through NCC 
blockade on the development of malignant arrhythmias and sudden death in dnNRSF-Tg 
mice, we administered subpressor doses of cilnidipine, a dual N- and L-type dihydropyridine 
Ca2+ channel blocker, or nitrendipine, a more L-type-selective dihydropyridine Ca2+ channel 
blocker, to dnNRSF-Tg mice for 24 weeks, beginning when they were 8 weeks of age. Under 
our experimental conditions, systolic blood pressures and heart rates did not differ among the 
control, cilnidipine and nitrendipine groups of dnNRSF-Tg mice, though blood pressures 
were slightly lower and heart rates were significantly slower in dnNRSF-Tg mice than in 
untreated WT mice, as previously reported (Systolic blood pressure: WT, 101.40±1.48; Tg, 
96.0±1.75; Tg+cilnidipine, 96.67±1.64; Tg+nitrendipine, 95.47±1.92 mmHg. Heart rates: WT, 
682.3±27; dnNRSF-Tg, 590.6±10.9; Tg+cilnidipine, 567.13±17.58; Tg+nitrendipine, 
568.8±11.07 /min) (Figure 1C and D)8.  We found that cilnidipine dramatically improved 
the survival rate among dnNRSF-Tg mice, as compared to mice treated with nitrendipine or 
untreated control (Figure 1E).  Although heart-to-body weight ratios were higher in 
dnNRSF-Tg than WT mice, as reported previously8, heart-to-body weight ratios did not 
significantly differ among the control, cilnidipine and nitrendipine groups of dnNRSF-Tg 
mice (WT, 4.08±0.31; Tg, 5.94±0.24; Tg+cilnidipine, 5.61±0.48; Tg+nitrendipine, 5.94±0.36 
mg/g) (Figure 2A). Lung-to-body weight ratios also did not differ among these three groups 
(WT, 5.28±0.37; Tg, 6.07±0.22; Tg+cilnidipine, 5.93±0.79; Tg+nitrendipine, 5.9±0.29 mg/g) 
(Figure 2B).  In addition, histological analyses, including determination of the %fibrotic 
area, and echocardiographic analyses also showed no significant differences among these 
three groups (Figure 2C, D, E and F, and Table 1).  By contrast, the echocardiography and 
histology showed that, as compared to untreated WT mice, left ventricular systolic function 
was diminished and %fibrotic area was increased in dnNRSF-Tg mice, as reported previously 
(Figure 2C, D, E and F, and Table 1)8. Consistent with these findings, there was no 





among the three groups, whereas their expression did differ between untreated WT mice and 
dnNRSF-Tg mice, as described previously (Figure 2G and H)8.   
Expression of the fibrosis-related genes Col1a1, Col3a1 and FN1, encoding collagen 
type1α1, collagen type3α1 and fibronectin 1, respectively, was not affected by the drug 
treatments (Supplemental Figure S1A, B and C).  Expression of genes encoding the 
fetal-type ion channels CACNA1H, HCN2 and HCN4 was higher in untreated dnNRSF-Tg 
ventricles than control WT ventricles, as reported previously, and cilnidipine did not affect 
expression these genes in dnNRSF-Tg ventricles (Supplemental Figure S1D,E and F).  
Collectively, all of these data indicate that cilnidipine suppresses sudden death in dnNRSF-Tg 
mice without significantly affecting cardiac structure or function.  
 
3.2 Cilnidipine improves cardiac autonomic nervous system function and reduces 
arrhythmicity in dnNRSF-Tg mice 
We hypothesized that correcting autonomic balance through NCC blockade reduces 
arrhythmogenicity, thereby improving survival among dnNRSF-Tg mice. HRV is a widely 
accepted index of cardiac autonomic nervous system activity19. Earlier frequency domain 
analysis of HRV revealed that patients with severe heart failure show a progressive reduction 
in power in both the low frequency (LF) and high frequency (HF) ranges19, and that reduction 
in the LF power range is a significant predictor of sudden cardiac death in patients with heart 
failure20.  We used HRV as an index to evaluate cardiac autonomic function in WT and 
dnNRSF-Tg mice, and examined the effects of cilnidipine on HRV19.  In mice, HRV 
predominantly correlates with parasympathetic activity21.  As we showed previously, both 
the LF and HF powers averaged over 24 h in dnNRSF-Tg mice (LF, 1.228±0.198; HF, 
0.823±0.186 msec2) were markedly lower than in WT mice (LF, 4.331±0.706; HF, 
2.412±0.089 msec2), indicating a general reduction in parasympathetic activity in 
dnNRSF-Tg mice (Figure 3A and B).  Cilnidipine dramatically increased the power in both 
the LF and HF ranges of HRV (LF, 3.308±0.338; HF, 2.228±0.283 msec2), whereas 
nitrendipine had little effect on HRV (LF, 0.538±0.447; HF, 1.383±0.57 msec2) (Figure 3A 
and B).  We also found that urinary excretion of norepinephrine, which is indicative of the 
level of sympathetic nerve activity, was significantly higher in dnNRSF-Tg than WT mice, 
and that norepinephrine excretion was significantly reduced only by cilnidipine (WT, 
0.09±0.02; Tg, 0.33±0.04; Tg+cilnidipine, 0.15±0.03; Tg+nitrendipine, 0.32±0.1 µg/day) 
(Figure 3C).   
     We next used an implanted telemetric monitoring system to examine the effects of 
cilnidipine and nitrendipine on electrocardiographic parameters in dnNRSF-Tg mice.  We 
found that only cilnidipine significantly suppressed the number of premature ventricular 
contractions (PVCs) in dnNRSF-Tg hearts (WT, 0±0; dnNRSF-Tg, 502.66±305.69; 





3D).  More importantly, it dramatically reduced the number of episodes of ventricular 
tachycardia (VT) (WT, 0±0; dnNRSF-Tg, 14.92±4.95; dnNRSF-Tg+cilnidipine, 0.06±0.06; 
dnNRSF-Tg+nitrendipine, 12.75±5.16 /hours) (Figure 3E and Supplemental Figure S2A and 
B).  These lines of evidence suggest that by restoring autonomic nervous system balance, 
cilnidipine reduces the incidence of lethal arrhythmias in dnNRSF-Tg mice. 
  
3.3 β-adrenergic receptor blockade prevents lethal arrhythmias and sudden death in 
dnNRSF-Tg mice 
To verify the importance of correcting autonomic nervous system imbalance for the 
prevention of lethal arrhythmias and sudden death in dnNRSF-Tg mice, irrespective of 
effects on structural remodeling, we examined the effects of treating these mice with a 
β-adrenergic receptor blocker. We administered a subpressor dose of the lipophilic 
β-adrenergic receptor blocker bisoprolol (1 mg/kg/day P.O.) to WT and dnNRSF-Tg mice. 
Although systolic blood pressures did not differ between untreated control and 
bisoprolol-treated mice (untreated WT, 107.5±1.6; WT+bisoprolol, 108.0±1.2; untreated Tg, 
98.6±2.0; Tg+bisoprolol, 98.6±1.7 mmHg) (Figure 3F), heart rates were significantly slower 
in bisoprolol-treated than untreated WT and dnNRSF-Tg mice (untreated WT, 697.8±8.3; 
WT+bisoprolol, 604.7±38.3; Tg, 601.6±10.1; Tg+bisoprolol, 558.6±12.0 /min) (Figure 3G). 
At the dose tested, bisoprolol also did not affect cardiac systolic function assessed 
echocardiographically in dnNRSF-Tg mice (LVDd: WT, 3.3±0.2; WT+bisoprolol, 3.2±0.1; 
Tg, 3.9±0.1; Tg+bisoprolol, 3.9±0.1 mm. EF: WT, 84.5±4.0; WT+bisoprolol, 83.0±1.5; Tg, 
46.0±1.6; Tg+bisoprolol, 51.5±2.7 %) (Figure 3H and I).  On the other hand, bisoprolol 
significantly restored power in both the LF and HF ranges of HRV (LF, untreated WT, 
5.19±0.37; Tg, 1.36±0.14; Tg+bisoprolol, 3.34±0.39 msec2. HF, untreated WT, 2.12±0.24; Tg, 
0.86±0.12; Tg+bisoprolol, 1.62±0.22 msec2) (Figure 3J and K) and reduced the incidence of 
VPCs and VTs in those mice (VPC: Tg, 408.3±122.9; Tg+bisoprolol 98.9±42.2 /hours; VT: 
Tg, 28.2±12.1; Tg+bisoprolol 7.6±1.7 /hours) (Figure 3L and M).  As a result, bisoprolol 
significantly improved survival rates among dnNRSF-Tg mice (Figure 3N).  These results 
strongly support our finding that imbalance of autonomic nervous system activities is 
critically involved in the occurrence of sudden arrhythmic death in dnNRSF-Tg mice. 
 
3.4 Genetic titration of NCC improves survival among dnNRSF-Tg mice 
To further confirm the benefit of NCC inhibition for prevention of sudden death in 
dnNRSF-Tg mice, we next genetically titrated NCC expression by crossing dnNRSF-Tg mice 
with mice lacking CACNA1B, encoding the α1B subunit of NCC.  Because the 
CACNA1B-/- genotype has a high incidence of early mortality from an as yet unknown cause, 
we compared the phenotypes of dnNRSF-Tg;CACNA1B+/+ mice with those of 





in dnNRSF-Tg;CACNA1B+/+ mice (Figure 4A).  The gross appearance of CACNA1B+/- 
mice is normal, and they show no early mortality.  Systolic blood pressures in 
dnNRSF-Tg;CACNA1B+/- and dnNRSF-Tg;CACNA1B+/+ mice did not significantly differ, 
but were mildly lower than in control WT (CACNA1B+/+) mice (WT, 101.25±7.26; 
CACNA1B+/-, 91.25±2.78; dnNRSF-Tg, 92±4.38; dnNRSF-Tg;CACNA1B+/-, 89.25±2.14 
mmHg) (Figure 4B).  Similarly, heart rates did not differ between 
dnNRSF-Tg;CACNA1B+/+ and dnNRSF-Tg;CACNA1B+/- mice, although they were slower 
in dnNRSF-Tg;CACNA1B+/+ than control WT mice, as reported previously (WT, 
632.25±26.36; CACNA1B+/-, 594±33.39; dnNRSF-Tg, 515.25±14.71; 
dnNRSF-Tg;CACNA1B+/-, 521.5±23.32 /min) (Figure 4C)8.  Body weights were 
comparable between the two dnNRSF-Tg groups (CACNA1B+/+, 31.08±1.11; CACNA1B+/-, 
29.53±1.37; dnNRSF-Tg;CACNA1B+/+, 28.86±1.19; dnNRSF-Tg;CACNA1B+/-, 27.41±1.09 
g) (Figure 4D), but heart-to-body weight ratios were higher in dnNRSF-Tg;CACNA1B+/+ 
than WT (CACNA1B+/+) mice and were significantly lower in dnNRSF-Tg;CACNA1B+/- 
than dnNRSF-Tg;CACNA1B+/+ mice (CACNA1B+/+, 4.44±0.04; CACNA1B+/-, 4.51±0.14; 
dnNRSF-Tg; CACNA1B+/+, 5.68±0.21; dnNRSF-Tg;CACNA1B+/-, 4.86±0.18 mg/g) (Figure 
4E). Lung-to-body weight ratios were comparable between the two dnNRSF-Tg groups 
(CACNA1B+/+, 5.06±0.22; CACNA1B+/-, 4.68±0.96; dnNRSF-Tg; CACNA1B+/+, 5.41±0.09; 
dnNRSF-Tg;CACNA1B+/-, 5.52±0.26 mg/g) (Figure 4F). Echocardiographic analysis 
showed that left ventricular diastolic dimension (LVDd) was higher in dnNRSF-Tg than WT 
mice, while ejection fraction (EF) was lower in dnNRSF-Tg;CACNA1B+/+ than WT mice, as 
was reported previously (Figure 5A and B)8. In addition, LVDd was lower and EF was higher 
in dnNRSF-Tg;CACNA1B+/- than dnNRSF-Tg;CACNA1B+/+ mice (Figure 5A and B, and 
Table 1).   
Histological analysis revealed no significant difference between 
dnNRSF-Tg;CACNA1B+/+ and dnNRSF-Tg;CACNA1B+/- mice, although %fibrotic area 
showed a trend toward being smaller in dnNRSF-Tg;CACNA1B+/- than 
dnNRSF-Tg;CACNA1B+/+ mice (Figure 5C and D).  Expression of the fibrosis-related 
genes Col1a1, Col3a1 and FN1 did not significantly differ between 
dnNRSF-Tg;CACNA1B+/+ and dnNRSF-Tg;CACNA1B+/- mice (Supplemental Figure S3A, B 
and C), though there was a significant difference in the expression of ANP and SERCA2 
between these two genotypes (Figure 5E and F).  Genetic reduction in CACNA1B also 
significantly affected expression of CACNA1H and HCN2, but not HCN4, in dnNRSF-Tg 
ventricles (Supplemental Figure S3D, E and F).  All of these data demonstrate that genetic 
reduction of CACNA1B tends to ameliorate impaired cardiac function and pathological 
remodeling in dnNRSF-Tg mice.  Furthermore, survival among dnNRSF-Tg;CACNA1B+/- 





mice (Figure 6A), demonstrating that reduction of NCC prevents sudden arrhythmic death in 
dnNRSF-Tg mice. 
 
3.5 Reducing CACNA1B expression improves autonomic function and decreases the 
occurrence of arrhythmias in dnNRSF-Tg mice  
We also assessed autonomic nervous system activity in dnNRSF-Tg;CACNA1B+/- and 
dnNRSF-Tg;CACNA1B+/+ mice.  In HRV analyses, the reductions in LF and HF power 
otherwise seen in dnNRSF-Tg;CACNA1B+/+ mice (LF, 1.288±0.16; HF, 1.168±0.108 msec2) 
were significantly ameliorated in dnNRSF-Tg;CACNA1B+/- mice (LF, 3.54±0.47; HF, 
3.075±0.468 msec2), indicating a restoration of parasympathetic activity through reduction of 
NCC function (Figure 6B and C).  In addition, we found that the increase in urinary 
excretion of norepinephrine seen in dnNRSF-Tg;CACNA1B+/+ mice (0.428±0.07 µg/day) 
was significantly ameliorated in dnNRSF-Tg;CACNA1B+/- mice (0.154±0.05 µg/day) 
(Figure 6D).  Finally, evaluation of arrhythmicity revealed that the incidences of both PVCs 
and VT were significantly lower in dnNRSF-Tg;CACNA1B+/- than 
dnNRSF-Tg;CACNA1B+/+ mice (VPC: WT, 0±0; CACNA1B+/-, 0±0; dnNRSF-Tg, 
239.08±27.93; dnNRSF-Tg;CACNA1B+/-, 3.21±3.21. VT: WT, 0±0; CACNA1B+/-, 0±0; 
dnNRSF-Tg, 41.3±12.69; dnNRSF-Tg;CACNA1B+/-, 0.36±0.36 /hours, ) (Figure 6E and F).  
These results demonstrate that genetic titration of CACNA1B, encoding NCC, corrected an 
imbalance between sympathetic and parasympathetic nervous system activities, which, at 
least in part, contributes to reducing malignant arrhythmias in dnNRSF-Tg mice in a manner 






Autonomic dysregulation leading to increased sympathetic nerve activity and reduced 
parasympathetic nerve activity is reportedly associated with the increased arrhythmicity seen 
in patients with chronic heart failure2, 22, 23.  NCCs play a major role in the release of 
norepinephrine at sympathetic nerve terminals7, 24.  Consequently, mice lacking CACNA1B, 
the gene encoding the α1 subunit of NCCs, exhibit a significantly impaired positive inotropic 
response7.  In the present study, we found that pharmacological blockade of NCCs or their 
genetic titration improved the balance between sympathetic and parasympathetic nerve 
activities and prevented the sudden death and arrhythmicity otherwise seen in dnNRSF-Tg 
mice, a mouse model of sudden arrhythmic death associated with cardiac dysfunction8.  The 
mode of death in these model mice is sudden and without overt edema, pleural effusion or 
apparent lung congestion, and all the telemetry data obtained at the time of death indicates 
VT/VF to be the cause8.  Moreover, in an earlier study we found that systemic 
administration of isoproterenol induced VT more frequently in dnNRSF-Tg than WT mice11. 
Conversely, administration of a β-blocker led to a significant reduction in the incidence of 
sudden death among dnNRSF-Tg mice under conditions in which cardiac systolic function 
and remodeling were not affected (Figure 3H-N). These findings suggest NCC blockade or 
genetic titration of NCC reduces the likelihood of sudden arrhythmic death, thereby 
improving survival.   
Pharmacological interventions that reduce cardiac sympathetic activity have been 
shown to protect against arrhythmias25, while interventions that stimulate cardiac sympathetic 
activity provoke malignant arrhythmias2, 26.  In patients with heart failure, β-adrenoreceptor 
blockade reduces the incidence of sudden death27, 28; however, β-blockers are not completely 
protective, and mortality remains high among patients with cardiac dysfunction, despite 
optimal β-blocker therapy27, 28.  It is therefore necessary to find other approaches to 
modulate sympathetic or parasympathetic activity.  In that context, a clinical trial testing the 
effect of central modulation of sympathetic activity using moxonidine SR in patients with 
heart failure was terminated early due to an increase in mortality and morbidity in patients 
receiving the drug29.  Thus strong central inhibition of the sympathetic nervous system 
through imidazoline receptor stimulation appears not to protect against lethal arrhythmias.  
NCCs are localized mainly at peripheral sympathetic nerve terminals, where they regulate the 
release of neurotransmitters (e.g., catecholamines), thereby modulating sympathetic 
activity4-6.  Our findings suggest that, by correcting their autonomic dysregulation, NCC 
blockade could be an effective approach to preventing sudden arrhythmic death in patients 
with heart failure.   
Cilnidipine failed to prevent the decline in cardiac function in dnNRSF-Tg mice, 
whereas genetic titration tended to ameliorate the adverse cardiac remodeling and cardiac 





for the difference in the effects on cardiac function between cilnidipine and genetic titration 
of NCCs remain unclear at present.  It may be that cilnidipine’s ability to block L-type Ca2+ 
channels has a detrimental effect on cardiac function, as L-type Ca2+ channel blockers can 
adversely affect the progression of heart failure30.  Other possibilities are that the relatively 
low dose of cilnidipine used in this study was not sufficient to prevent the progression of 
cardiac dysfunction, though it did prevent lethal arrhythmias, or that the NCC inhibition 
achieved in CACNA1B+/- mice was more prolonged and more stable than that achieved with 
cilnidipine, which was not started until the mice were 8 weeks of age.  The effects on NCCs 
expressed in the central nervous system could also differ between cilnidipine and genetic 
titration, as cilnidipine has little ability to cross the blood-brain barrier31. These differences 
suggest the underlying mechanisms involved in the reduced incidence of lethal arrhythmias 
and the prolonged survival differ somewhat between cilnidipine treatment and genetic 
titration of CACNA1B in this study.  Cilnidipine treatment, which improved autonomic 
imbalance and reduced lethal arrhythmias without affecting cardiac remodeling, mainly 
suppressed the triggering of lethal arrhythmias induced by autonomic imbalance.  On the 
other hand, genetic titration of CACNA1B, which improved autonomic imbalance and also 
tended to prevent adverse cardiac remodeling, suppressed lethal arrhythmias and improved 
survival in two ways: it inhibited the triggering of arrhythmias and also suppressed the 
generation of arrhythmogenic substrates.  In both cases, correcting the autonomic imbalance 
associates with a reduction in the incidence of sudden death attributable to lethal arrhythmias 
in dnNRSF-Tg.  However, because it is not possible to completely exclude the possibility 
that some dnNRSF-Tg mice (especially older mice) die due to congestive heart failure, 
irrespective of arrhythmias, there is a possibility that genetic deletion of NCC may also 
prevent this mode of death in addition to sudden arrhythmic death in dnNRSF-Tg mice 
through suppression of excessive sympathetic activity.  
In the present study, both pharmacological blockade of NCCs and their genetic titration 
not only repressed sympathetic activity, as demonstrated by a reduction in urinary 
norepinephrine levels, but also restored parasympathetic activity, as indicated by HRV 
analyses.  The precise mechanism by which NCC inhibition improves parasympathetic 
activity is not clear at present.  However, accumulating data indicate the sympathetic and 
parasympathetic nervous systems interact via several mechanisms at both the central and 
peripheral levels of the neuraxis32.  NCC inhibition-induced reductions in sympathetic 
activity may affect these interactions, ameliorating the reduction in parasympathetic activity, 
as was observed in dnNRSF-Tg mice.  In humans, cilnidipine reportedly enhances 
parasympathetic activity in hypertensive patients while exerting a concomitant 
sympathoinhibitory effect12, 13.  Moreover, there is now much evidence showing the 
anti-arrhythmic effects of parasympathetic nervous activation.  This suggests that, in 





contributes to the protective effects of NCC inhibition observed in this study27.  Although 
further investigation is necessary, our study suggests that agents able to selectively block 
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Figure 1.  Pharmacological blockade of NCCs by cilnidipine improves survival among 
dnNRSF-Tg mice.  A, Relative levels of CACNA1B mRNA in brains (B) from wild-type 
(WT), kidney (K) from WT, cardiac ventricle (V) from WT and cardiac ventricle (V) from 
8-week-old dnNRSF-Tg mice (Tg); levels in cardiac ventricle from WT mice were assigned a 
value of 1.0.  n=3 each for brain, kidney and cardiac ventricle from WT mice and 2 for 
cardiac ventricle from dnNRSF-Tg mice.  B, Relative levels of CACNA1B, CACNA1H and 
CACNA1C mRNA in cardiac ventricle from 8-week-old WT mice and dnNRSF-Tg mice 
(Tg); levels of CACNA1B mRNA in WT mice were assigned a value of 1.0.  n=5 for WT 
mice and 7 for dnNRSF-Tg.  C and D, Systolic blood pressures (C) and heart rates (D) in 
20-week-old untreated WT, untreated Tg (Tg-cont), cilnidipine-treated Tg (Tg-Cil) and 
nitrendipine-treated Tg-Nit mice (n=15 each for untreated Tg, Tg-Cil and Tg-Nit, and 10 for 
untreated WT). ANOVA with post hoc Fisher’s tests was used for analysis. *p<0.05. N.S.: 
not significant.  E, Kaplan-Meyer survival curves for untreated WT, untreated Tg, 
Cil-treated Tg and Nit-treated Tg over a 24-week drug administration period (from 8 to 32 
weeks of age): Log-rank test was used for analysis. *p<0.05 (n = 21 for WT, 23 for Tg 
without drugs, 22 for Tg + Cil, 20 for Tg + Nit). The numbers of mice alive in each group at 
the end of each period are shown at the bottom of the figure. All data except survival curves 
are shown as means ± SEM. 
 
Figure 2.  Cilnidipine does not affect cardiac structure or function in dnNRSF-Tg mice.  A 
and B, heart-to-body weight (HW/BW) ratios (A) and lung-to-body weight (LungW/BW) 
ratios (B) in 20-week-old untreated WT (WT-cont), untreated Tg (Tg-cont), Cil-treated Tg 
(Tg-Cil) and Nit-treated Tg (Tg-Nit) mice (n=5 for untreated WT, 4 for Tg-cont, 4 for Tg-Cil 
and 3 for Tg-Nit).  C, Histology of hearts from 20-week-old untreated WT, Tg-cont, Tg-Cil 
and Tg-Nit mice: H-E, hematoxylin-eosin staining; Sirius-red, Sirius-red staining.  Scale 
bars, 100 µm.  D, %fibrotic area in 20-week-old untreated WT, Tg-cont, Tg-Cil and Tg-Nit 
mice (n=5 for Tg-cont, n=7 for Tg-Cil).  N.S.: not significant.  E and F, Left ventricular 
end-diastolic dimension (LVDd) (E) and ejection fraction (EF) (F) assessed 
echocardiographically in untreated WT, Tg-cont, Tg-Cil and Tg-Nit mice. *p<0.05. N.S.: not 
significant.  (n=5 each for untreated WT, Tg-cont and Tg-Cil, n=7 for Tg-Nit).  G and H, 
Relative levels of ANP (G) and SERCA2 (H) mRNA in cardiac ventricles from untreated WT, 
Tg-cont, Tg-Cil and Tg-Nit mice; levels in untreated WT were assigned a value of 1.0.  
N.S.: not significant. (n=4 each). ANOVA with post hoc Fisher’s tests was used for analysis.. 






Figure 3.  Cilnidipine restores cardiac autonomic nervous system balance and reduces 
arrhythmias in dnNRSF-Tg mice.  A and B, Average power of the low frequency (LF) (A) 
and high frequency (HF) (B) components of heart rate variability (HRV) recorded over a 24-h 
period in 20-week-old untreated WT (WT-cont), untreated Tg (Tg-cont), Cil-treated Tg 
(Tg-Cil) and Nit-treated (Tg-Nit) mice. *p<0.05. N.S.: not significant (n = 5 for WT, 6 for 
Tg-cont, 8 for Tg-Cil, 6 for Tg-Nit).  C, Urinary norepinephrine (NE) levels in 20-week-old 
WT-cont, Tg-cont, Tg-Cil and Tg-Nit mice. *p<0.05. N.S.: not significant (n = 7 for WT, 7 
for Tg-cont, 5 for Tg-Cil, 4 for Tg-Nit).  D and E, Numbers of PVC (D) and VT (E) 
recorded with a telemetry system in 20-week-old WT-cont, Tg-cont, Tg-Cil and Tg-Nit mice 
are shown by dot plots. *p<0.0083, N.S.: not significant (n = 5 for WT-cont, 6 for Tg-cont, 8 
for Tg-Cil, 6 for Tg-Nit).  F and G, Systolic blood pressures (F) and heart rates (G) in 
20-week-old untreated WT (WT-cont), bisoprolol (Bis)-treated WT (WT-Bis), untreated Tg 
(Tg-cont) and Bis-treated Tg (Tg-Bis) mice (n=4 for WT-cont, 3 for WT-Bis, 5 for Tg-cont 
and Tg-Bis). H and I, Left ventricular end-diastolic dimension (LVDd) (H) and ejection 
fraction (EF) (I) assessed echocardiographically in WT-cont, WT-Bis, Tg-cont and Tg-Bis 
mice. *p<0.05. N.S.: not significant.  (n=4 for WT-cont, 3 for WT-Bis, 5 for Tg-cont and 
Tg-Bis). J and K, Average power of the low frequency (LF) (J) and high frequency (HF) (K) 
components of heart rate variability (HRV) recorded over a 24-h period in 20-week-old 
WT-cont, Tg-cont and Tg-Bis mice. *p<0.05. N.S.: not significant (n = 4 for WT-cont, 6 for 
Tg-cont, 7 for Tg-Bis). L and M, Numbers of PVC (L) and VT (M) recorded with a telemetry 
system in 20-week-old Tg-cont and Tg-Bis mice are shown by dot plots. *p<0.05 (n = 6 for 
Tg-cont, 7 for Tg-Bis). ANOVA with post hoc Fisher’s tests was used for analysis, except for 
numbers of arrhythmias (D, E, L, and M). Numbers of arrhythmias among the four groups 
were analyzed using Kruskal-Wallis nonparametric ANOVA followed by the Bonferroni 
correction (D and E). Numbers of arrhythmias between two groups were analyzed using 
non-parametric Mann-Whitney test (L and M). N, Kaplan-Meyer survival curves for 
untreated Tg and Biso-treated Tg (Tg+Bis) over a 90-days drug administration period (from 
12 to 25 weeks of age): Log-rank test was used for the survival analysis. *p<0.05 (n = 15 
each). The numbers of mice alive in each group at the end of each period are shown at the 
bottom of the figure. All data except numbers of arrhythmias and survival curves are shown 
as means ± SEM. 
 
 
Figure 4.  Effects of genetic titration of CACNA1B on hemodynamics and heart size in WT 
and dnNRSF-Tg mice.  A, CACNA1B mRNA expression in brains from 8-week-old 
CACNA1B+/+, CACNA1B+/- and CACNA1B-/- mice; the level in CACNA1B+/+ brain was 
assigned a value of 1.0.  B and C, Systolic blood pressures (B) and heart rates (C) in 





dnNRSF-Tg;CACNA1B+/- mice.  N.S.: not significant (n = 4 each).  D, E and F, body 
weights (BW)(D), heart-to-body weight ratios (HW/BW) (E) and lung-to-body weight ratios 
(LungW/BW) (F) in 20-week-old CACNA1B+/+, CACNA1B+/-, dnNRSF-Tg;CACNA1B+/+ 
and dnNRSF-Tg;CACNA1B+/- mice.  *p<0.05. N.S.: not significant. (BW and HW/BW: 
n=4 for CACNA1B+/+, 6 for CACNA1B+/-, 5 for dnNRSF-Tg;CACNA1B+/+, 7 for 
dnNRSF-Tg;CACNA1B+/-. LungW/BW: n=4 for CACNA1B+/+, 6 for CACNA1B+/- and 
dnNRSF-Tg;CACNA1B+/-, 5 for dnNRSF-Tg;CACNA1B+/+). ANOVA with post hoc 
Fisher’s tests was used for analysis. All data are shown as means ± SEM. 
 
 
Figure 5.  Effect of genetic titration of CACNA1B on cardiac structure and function in 
dnNRSF-Tg mice.  A and B, Left ventricular end-diastolic dimension (LVDd) and ejection 
fraction (EF) assessed echocardiographically in 20-week-old CACNA1B+/+, CACNA1B+/-, 
CACNA1B+/+; dnNRSF-Tg and CACNA1B+/-; dnNRSF-Tg mice. *p<0.05. (n = 13 for 
CACNA1B+/+, 14 for CACNA1B+/-, 11 for dnNRSF-Tg;CACNA1B+/+, 15 for 
dnNRSF-Tg;CACNA1B+/-).  C, Histology of hearts from 20-week-old CACNA1B+/+, 
CACNA1B+/-, dnNRSF-Tg;CACNA1B+/+ and dnNRSF-Tg;CACNA1B+/- mice.  H-E, 
hematoxylin-eosin staining; Sirius-red, Sirius-red staining.  Scale bars, 100 µm.  
D, %Fibrotic area in the indicated groups (n=4 for CACNA1B+/+, 6 for CACNA1B+/-, 5 for 
dnNRSF-Tg;CACNA1B+/+, 7 for dnNRSF-Tg;CACNA1B+/-).  N.S.: not significant.  E and 
F, Relative levels of ANP and SERCA2 mRNA in cardiac ventricles from 20-week-old 
CACNA1B+/+, CACNA1B+/-, dnNRSF-Tg;CACNA1B+/+ and dnNRSF-Tg;CACNA1B+/- 
mice (n = 4 for CACNA1B+/+, 6 for CACNA1B+/-, 5 for dnNRSF-Tg;CACNA1B+/+ and 
dnNRSF-Tg;CACNA1B+/-); levels in CACNA1B+/+ ventricles were assigned a value of 1.0.  
*p<0.05. ANOVA with post hoc Fisher’s tests was used for analysis. All data are shown as 
means ± SEM. 
 
Figure 6.  Genetic titration of CACNA1B restores cardiac autonomic nervous system 
balance and reduces arrhythmias in dnNRSF-Tg mice.  A, Kaplan-Meyer survival curves for 
CACNA1B+/+ (1B+/+), CACNA1B+/- (1B+/-), dnNRSF-Tg;CACNA1B+/+ (Tg/1B+/+) and 
dnNRSF-Tg;CACNA1B+/- (Tg/1B+/-) mice.  Curves cover the span from birth to 32 weeks 
of age. Log-rank test was used for analysis. *p<0.05 (n=22 for CACNA1B+/+, 38 for 
CACNA1B+/-, 20 for dnNRSF-Tg;CACNA1B+/+, 42 for dnNRSF-Tg;CACNA1B+/-). The 
numbers of mice alive in each group at the end of each period are shown at the bottom of the 
figure. B and C, Average power of the low frequency (LF) (B) and high frequency (HF) (C) 
components of heart rate variability (HRV) recorded over a 24-h period in 20-week-old 
CACNA1B+/+, CACNA1B+/-, dnNRSF-Tg;CACNA1B+/+ and dnNRSF-Tg;CACNA1B+/- 





7 for dnNRSF-Tg;CACNA1B+/-).  D, Urinary norepinephrine (NE) levels in 20-week-old 
CACNA1B+/+, CACNA1B+/-, dnNRSF-Tg;CACNA1B+/+ and dnNRSF-Tg;CACNA1B+/- 
mice. *p<0.05 (n=5 for CACNA1B+/-, 6 for CACNA1B+/+, dnNRSF-Tg;CACNA1B+/+ and 
dnNRSF-Tg;CACNA1B+/-).  E and F, Numbers of PVC (E) and VT (F) recorded using a 
telemetry system in 20-week-old CACNA1B+/+, CACNA1B+/-, dnNRSF-Tg;CACNA1B+/+ 
and dnNRSF-Tg;CACNA1B+/- mice are shown by dot plot. *p<0.0083 (n=5 for 
CACNA1B+/+, 7 for CACNA1B+/-, 6 for dnNRSF-Tg;CACNA1B+/+, 7 for 
dnNRSF-Tg;CACNA1B+/-). All data in B-D are shown as means ± SEM.  ANOVA with 
post hoc Fisher’s tests was used for analysis, except for numbers of arrhythmias (E and F).  
Numbers of arrhythmias were analyzed using Kruskal-Wallis nonparametric ANOVA 






Table 1.  Echocardiographic parameters in 20-week-old mice.  
 
Pharmacological inhibition 
      WT                   dnNRSF-Tg             
  control cont Cil Nit 
  LVDd (mm) 3.3±0.13 3.9±0.19 4.0±0.11 3.8±0.08 
  LVDs (mm) 2.1±0.08 3.1±0.17 3.1±0.11 2.9±0.10 
  IVST (mm) 0.76±0.02 0.72±0.02 0.72±0.02 0.71±0.03 
  PWT (mm) 0.76±0.02 0.74±0.02 0.76±0.02 0.76±0.03 
  FS (%) 36.1±2.3 20.3±1.4 23.3±2.7 23.8±2.4 
  EF (%) 73.2±2.7 49.0±2.3 55.4±4.2 57.0±4.3 
Genetic titration  
           dnNRSF-Tg          
  1B+/+ 1B+/- 1B+/+ 1B+/- 
  LVDd (mm) 3.2±0.10 3.3±0.08 4.1±0.12 3.3±0.07* 
  LVDs (mm) 2.2±0.12 2.2±0.06 3.2±0.13 2.3±0.08* 
  IVST (mm) 0.66±0.01 0.68±0.02 0.66±0.02 0.69±0.02 
  PWT (mm) 0.68±0.02 0.67±0.02 0.66±0.02 0.68±0.02 
  FS (%) 31.8±1.8 33.1±1.9 20.4±1.3 30.4±1.3* 
  EF (%) 66.4±2.4 68.9±2.6 49.0±2.4 64.3±1.8* 
 
Values are means ± SEM.  Cil, cilnidipine; Nit, nitrendipine; 1B+/+, CACNA1B+/+; 1B+/-, 
CACNA1B+/-; LVDd, left ventricular diastolic dimension; LVDs, left ventricular systolic 
dimension; FS, fractional shortening; IVST, intraventricular septum wall thickness; PWT, 
posterior wall thickness.  Numbers of mice tested in the pharmacological inhibition study 
are as follows: n = 5 for WT, untreated dnNRSF-Tg and Cil-treated dnNRSF-Tg;7 for 
Nit-treated dnNRSF-Tg (upper panel). Numbers of mice tested in the genetic titration study 
are as follows: n = 13 for 1B+/+, 14 for 1B+/-, 11 for dnNRSF-Tg;1B+/+ and 15 for 
dnNRSF-Tg; 1B+/- (lower panel). ANOVA with post hoc Fisher’s tests was used for the 
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